Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024.
As a generic and bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug secured global sales exceeding $5 billion in 2022, as reported by IQVIA.
The development of Liraglutide showcases Adalvo's capability to host a diverse and comprehensive diabetes portfolio, covering both complex peptide injectables and small molecule oral treatments.
Adalvo is on target to secure one of the first generic approvals for Victoza® in Europe, reinforcing our commitment to pioneering advancements in diabetes care.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!
paulo.rodriguez@adalvo.com – Europe
marta.puig@adalvo.com - South Europe
marc.nolasco@adalvo.com - West Europe
jose.rendueles@adalvo.com- North Europe, CEE & APAC
supreet.sharma@adalvo.com – North America & Canada
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
bruno.alves@adalvo.com - Brazil & MENA
ajish.rajan@adalvo.com – Brands & Specialty Products
arni.baldursson@adalvo.com - Head of Global BD&L
Click on your preferred Business Partner and get in touch today!